Zevra Therapeutics, Inc.

Zevra sells two approved rare-disease medicines in the United States and is developing celiprolol for vascular Ehlers-Danlos syndrome, with most current commercial value concentrated in MIPLYFFA for Niemann-Pick disease type C.

Ticker

ZVRA

Company

Zevra Therapeutics, Inc.

Exchange

NasdaqGS

Listing

listed

Sector

Rare-Disease Biotech

The bull case is that MIPLYFFA can become a durable treatment for a tiny, underserved NPC population while better diagnosis, U.S. reimbursement, expanded access and future geographic approvals expand revenue, supported by a cash-rich balance sheet and the celiprolol pipeline. The countercase is that the commercial base is extremely concentrated, Q1 earnings were distorted by a one-time asset sale, the EU review received a negative CHMP opinion, OLPRUVA has already suffered a major impairment and celiprolol remains years from a proven Phase 3 outcome.S1S2S3S4S5S8

• Zevra Therapeutics, Inc. is listed on the Nasdaq Global Select Market under ZVRA. It is a commercial-stage rare-disease company whose current approved products are MIPLYFFA and OLPRUVA.S1S2
• MIPLYFFA, or arimoclomol, was approved by the FDA on September 20, 2024. Its approved use is in combination with miglustat for neurological manifestations of Niemann-Pick disease type C in adults and children age two and older.S4
• MIPLYFFA was the first FDA-approved treatment for NPC. The pivotal randomized trial included 50 patients, while the efficacy population consisted of 39 patients receiving background miglustat.S4
• In that efficacy population, the mean 12-month change in the four-domain NPC severity score was negative 0.2 with MIPLYFFA plus miglustat versus positive 2.0 with placebo plus miglustat, a difference of negative 2.2 with a 95% confidence interval from negative 3.8 to negative 0.6.S4
• Zevra estimates approximately 2,000 people with NPC across the United States and Europe, including about 900 in the United States, but only 300 to 350 diagnosed U.S. patients. These are company estimates, not an independently measured addressable market.S1
• Q2 2026 net revenue was $39.663 million versus $25.881 million a year earlier, an increase of 53.3%. First-half revenue was $75.883 million against $46.282 million, an increase of 64.0%.S9S10
• Q2 revenue included $30.2 million from MIPLYFFA, $0.2 million from OLPRUVA, $9.0 million of global expanded-access reimbursements, and $0.3 million of past-due AZSTARYS royalties and other reimbursements. MIPLYFFA rose from $24.6 million in Q1 while expanded-access reimbursements fell from $10.2 million, so the commercial product is carrying more of the total than a quarter earlier.S10
• Zevra received 14 MIPLYFFA prescription enrollment forms during Q2 2026, bringing the total to 184 since launch. An enrollment form starts a benefits investigation and may lead to a 30-day paid dispense; it is not the same as a confirmed ongoing paid patient. The quarterly addition is the number to watch, and 14 is a slower pace than the 170 accumulated in the six quarters before it.S10
• Management reported MIPLYFFA access unchanged at 69% of covered lives and 132 patients in the global expanded-access program at June 30, 2026, up from 122 three months earlier. Both are issuer-reported operating metrics.S10
• Q2 operating expenses were $21.045 million, including $4.486 million of research and development and $16.559 million of selling, general and administrative expense, and $3.0 million of non-cash stock compensation. Cost of product revenue fell to $1.525 million from $12.379 million a year earlier.S2S3
• Q2 GAAP net income was $8.752 million, or $0.14 per basic and diluted share, and income from operations was $16.777 million with no one-time gain inside the quarter. The prior-year quarter's $74.707 million contained a $148.325 million priority-review-voucher gain against a $58.710 million impairment, so the year-over-year comparison is between two very different quarters. First-half net income of $46.642 million still rests largely on the $43.314 million Commave asset-sale gain booked in Q1.S2S3S7
• The same quarter also included a $2.756 million loss on debt extinguishment, a $7.216 million loss on a derivative liability and payoff premium, and $6.914 million of income-tax expense.S2S3
• Zevra presented estimated adjusted Q2 net income of $15.2 million, or $0.25 per diluted share, after removing $6.4 million of non-cash warrant and CVR fair-value adjustments. This is a company-defined non-GAAP measure, not GAAP earnings.S3
• First-half operating cash flow was positive $23.174 million versus negative $11.823 million a year earlier, of which $6.142 million fell in Q1. The half also contained Commave transaction effects and working-capital movements, so two quarters do not establish durable cash generation.S9
• At June 30, 2026, Zevra held $145.321 million of cash, $76.249 million of current investments and $38.609 million of noncurrent investments, for $260.2 million of cash, cash equivalents and investments, against $236.8 million three months earlier. The cash line alone rose from $95.6 million, but part of that is investments maturing into cash rather than new money.S9
• Zevra repaid $60.092 million of debt principal during Q1 and terminated the related credit agreement. The June 30, 2026 balance sheet carries no long-term debt at all, against $61.928 million at the end of 2025.S2S3S7
• Common shares outstanding were 59.342 million at June 30, 2026. The company-reported fully diluted count was 69.298 million, including 7.427 million shares from equity awards and 2.529 million from warrants. Fully diluted shares grew by roughly 0.35 million over the quarter.S9S10
• OLPRUVA generated only $0.2 million of Q2 revenue, less than in Q1. In 2025, Zevra impaired $58.7 million of OLPRUVA-related intangible assets after revised commercial expectations and also recorded $11.7 million of inventory obsolescence expense.S1S3
• DiSCOVER is a randomized, placebo-controlled Phase 3 trial of celiprolol in COL3A1-positive vascular Ehlers-Danlos syndrome. ClinicalTrials.gov lists a target of approximately 150 patients and estimated primary completion in March 2029.S8
• Zevra enrolled four more DiSCOVER patients in Q2 2026, reaching 66 enrolled and three confirmed events at June 30, 2026. That is well below the approximately 150-patient target and does not establish efficacy. At four patients per quarter the target is many years away.S9S10S8
• On July 24, 2026, the European medicines committee CHMP adopted a negative opinion on the arimoclomol marketing-authorization application. Zevra confirmed on August 5 that it has submitted the re-examination request, so this is a major setback but not yet a final European Commission decision.S5
• Zevra reported Q2 2026 results after the market close on August 5, 2026 and filed the Form 10-Q for the June quarter the same day. This explainer is built on that quarter.S9S10

• narrativeLaunch interpretation: MIPLYFFA revenue, reimbursement coverage and enrollment activity suggest genuine U.S. commercial traction. The tiny diagnosed population means each patient can matter, but it also creates concentration, access and saturation risk.
• narrativeDiagnosis interpretation: better awareness and diagnosis could expand the treatable NPC population beyond today's known patients. Company population estimates do not prove how quickly, cheaply or reliably those patients can be found and treated.
• narrativePipeline interpretation: celiprolol could add a second meaningful rare-disease franchise if DiSCOVER succeeds. The study is event-driven, enrollment is incomplete and the registry currently points to 2029 primary completion.
• narrativeBalance-sheet interpretation: PRV and SDX asset sales funded a strong net-cash position and removed debt. Those transactions improve strategic flexibility but are not recurring product economics.

• ▸The next scheduled report is Q3 2026. The European re-examination decision and the pace of DiSCOVER enrollment can both land before it, so the quarterly cadence is not the only thing that dates this explainer.S5S8
• ▸The negative CHMP opinion is a direct setback to European expansion. Re-examination can change an opinion, but Zevra has not yet secured EU marketing authorization.S5
• ▸First-half GAAP profit is still dominated by the $43.3 million one-time asset-sale gain booked in Q1. Q2 stands on its own without such a gain, but a single clean quarter should not be annualized into recurring operating earnings.S9S10
• ▸$9.0 million of Q2 revenue came from expanded-access reimbursements whose pricing and clawback estimates can change. It is not identical to ordinary U.S. commercial product revenue, and it fell from $10.2 million in Q1 while total revenue rose.S1S10
• ▸The addressable NPC population is extremely small and underdiagnosed. Zevra estimates only 300 to 350 diagnosed U.S. patients, which limits volume and makes each start, discontinuation and reimbursement decision meaningful.S1
• ▸Enrollment forms are not paid-patient counts. A form only starts benefits investigation and may lead to an initial 30-day paid dispense.S1S2
• ▸Zevra relies on a single specialty pharmacy as the sole distributor and current product-sales customer for both approved U.S. products. Operational or financial disruption at that partner could hit availability and recognized revenue.S1S2
• ▸OLPRUVA's $0.2 million Q2 revenue, $58.7 million 2025 intangible impairment and $11.7 million inventory obsolescence charge show that an FDA approval does not guarantee commercial success.S1S3
• ▸MIPLYFFA's FDA evidence came from a very small rare-disease trial, with 39 patients in the miglustat efficacy population. Small samples increase uncertainty around effect size, subgroup conclusions and safety characterization.S4
• ▸MIPLYFFA must be used with miglustat for its approved indication. Safety warnings include hypersensitivity reactions, and common adverse reactions include respiratory infections, diarrhea and decreased weight.S4
• ▸DiSCOVER remained below half of its approximately 150-patient target at June 30, 2026 at 66 enrolled patients and three confirmed events. Event-driven development can take longer than calendar-based investor expectations.S9S10S8
• ▸The company has a history of recurring negative operating cash flows and repeats in the Q2 filing that it cannot guarantee consistently positive operating cash flow. Two positive quarters are not enough to erase that history.S1S9
• ▸Fully diluted shares exceeded basic shares by approximately 9.8 million at quarter end through awards and warrants. Future equity issuance or award vesting can dilute ownership.S2S3
• ▸Zevra depends on third parties for manufacturing, distribution, clinical execution and parts of commercialization. Failures, shortages, quality problems or regulatory noncompliance can interrupt supply or development.S1
• ▸Rare-disease pricing and reimbursement are politically and commercially sensitive. Coverage percentages do not guarantee patient affordability, unrestricted access or durable net pricing.S1S3
• ▸PRV and SDX sales supplied large nonrecurring gains and cash. Future results will depend more heavily on product economics after those assets and related royalties have been monetized.S1S2S7

NPC

— Niemann-Pick disease type C, a rare inherited disorder that causes harmful lipid accumulation and progressive neurological damage.

MIPLYFFA

— Zevra's brand name for arimoclomol, approved in the United States with miglustat for neurological manifestations of NPC.

Miglustat

— The background medicine that must be used with MIPLYFFA under the FDA-approved indication.

OLPRUVA

— Zevra's sodium phenylbutyrate product approved for chronic management of certain urea-cycle disorders.

Urea-cycle disorder

— A genetic disorder that impairs the body's ability to remove ammonia created when protein is broken down.

Prescription enrollment form

— A prescription submitted to Zevra's specialty pharmacy that starts benefits investigation and may lead to a paid dispense.

Covered lives

— People enrolled in health plans whose coverage rules are included in an access calculation; it is not a count of treated patients.

Expanded access program

— A regulatory route that can provide an investigational or not-yet-locally-approved medicine to eligible patients outside a standard commercial launch.

Clawback liability

— An estimate of revenue that may need to be repaid if a final reimbursed price is lower than the provisional expanded-access price.

CHMP

— The European Medicines Agency committee that issues scientific opinions on human-medicine marketing applications.

MAA

— Marketing Authorization Application, the regulatory application seeking permission to market a medicine in the European Union.

Re-examination

— A European procedure allowing an applicant to ask the CHMP to reconsider its opinion using specified grounds and further review.

vEDS

— Vascular Ehlers-Danlos syndrome, a rare inherited connective-tissue disorder associated with fragile arteries and organs.

Celiprolol

— The drug candidate Zevra is testing against placebo in the Phase 3 DiSCOVER vEDS study.

Event-driven trial

— A trial whose main analysis depends on reaching a required number of defined clinical events rather than only a fixed calendar date.

PRV

— Priority Review Voucher, a transferable FDA voucher that can shorten review time for a future eligible drug application.

SDX portfolio

— Zevra's former serdexmethylphenidate assets, including AZSTARYS-related rights and KP1077, sold to Commave in 2026.

Intangible impairment

— An accounting charge recorded when a nonphysical asset's carrying value is no longer recoverable from expected future cash flows.

Non-GAAP

— A company-defined financial measure that adjusts accounting results and may not be comparable across companies.

Fully diluted shares

— Outstanding common shares plus additional shares that could arise from instruments such as awards and warrants under the stated method.